Research graph
References from Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
SARS-CoV-2: an emerging coronavirus that causes a global threat
10.7150/ijbs.45053 · 2020 · External reference
10.1016/s0140-6736(20)30211-7
10.1016/s0140-6736(20)30211-7 · External reference
Coronavirus envelope protein: current knowledge
10.1186/s12985-019-1182-0 · 2019 · External reference
Emergence of a novel human coronavirus threatening human health
10.1038/s41591-020-0796-5 · 2020 · External reference
Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction
10.1080/20477724.2015.1122852 · 2016 · External reference
10.1080/22221751.2020.1723441
10.1080/22221751.2020.1723441 · External reference
COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't
10.1071/ma20013 · 2020 · External reference
10.1111/all.14238
10.1111/all.14238 · External reference
10.1016/s2213-2600(20)30079-5
10.1016/s2213-2600(20)30079-5 · External reference
Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore
10.1001/jama.2020.3204 · 2020 · External reference
10.1016/j.jaut.2020.102433
10.1016/j.jaut.2020.102433 · External reference
Coronavirus infections: epidemiological, clinical and immunological features and hypotheses
10.15698/cst2020.04.216 · 2020 · External reference
A novel coronavirus capable of lethal human infections: an emerging picture
10.1186/1743-422x-10-66 · 2013 · External reference
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
10.2807/1560-7917.es.2020.25.3.2000045 · 2020 · External reference
10.1007/s00330-020-06801-0
10.1007/s00330-020-06801-0 · External reference
Treatment options for COVID-19: the reality and challenges
10.1016/j.jmii.2020.03.034 · 2020 · External reference
SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction
10.3390/ijms21124549 · 2020 · External reference
10.1038/nature12711
10.1038/nature12711 · External reference
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
2020 · External reference
Vasopressin and its analogues in shock states: a review
10.1186/s13613-020-0628-2 · 2020 · External reference
Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
2020 · External reference
A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus Disease 2019 (COVID-19)
10.7759/cureus.7560 · 2020 · External reference
Outcomes in patients with COVID-19 infection taking ACEI/ARB
2020 · External reference
10.3332/ecancer.2020.1022
10.3332/ecancer.2020.1022 · External reference
COVID-19 pathophysiology: A review
10.1016/j.clim.2020.108427 · 2020 · External reference
CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China
10.1016/j.jinf.2020.04.004 · 2020 · External reference
Managing cutaneous immune-mediated diseases during the COVID-19 pandemic
10.1007/s40257-020-00514-2 · 2020 · External reference
10.1016/j.chom.2020.04.009
10.1016/j.chom.2020.04.009 · External reference
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
10.1016/j.ebiom.2020.102768 · 2020 · External reference
10.1016/j.cytogfr.2020.04.004
10.1016/j.cytogfr.2020.04.004 · External reference
10.1007/s11357-020-00186-0
10.1007/s11357-020-00186-0 · External reference
10.1016/s0140-6736(20)30628-0
10.1016/s0140-6736(20)30628-0 · External reference
COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?
10.1007/s00395-020-0791-5 · 2020 · External reference
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
10.1080/22221751.2020.1747363 · 2020 · External reference
10.1038/s41422-020-0305-x
10.1038/s41422-020-0305-x · External reference
10.1038/s41584-020-0419-z
10.1038/s41584-020-0419-z · External reference
Immune-epidemiological parameters of the novel coronavirus – a perspective
10.1080/1744666x.2020.1750954 · 2020 · External reference
COVID-19: immunology and treatment options
10.1016/j.clim.2020.108448 · 2020 · External reference
10.1080/22221751.2020.1746199
10.1080/22221751.2020.1746199 · External reference
Combination of biodata mining and computational modelling in identification and characterization of ORF1ab polyprotein of SARS-CoV-2 isolated from oronasopharynx of an Iranian patient
10.1186/s12575-020-00121-9 · 2020 · External reference
10.1080/22221751.2020.1719902
10.1080/22221751.2020.1719902 · External reference
Unresolved reference
External reference
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020
10.2807/1560-7917.es.2020.25.11.2000266 · 2020 · External reference
10.1097/inf.0000000000002660
10.1097/inf.0000000000002660 · External reference
Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China
2020 · External reference
Implications for forensic death investigations from first Swiss post-mortem CT in a case of non-hospital treatment with COVID-19
10.1016/j.fri.2020.200378 · 2020 · External reference
Deep learning system to screen coronavirus disease 2019 pneumonia
2020 · External reference
Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China
2020 · External reference
10.1021/acscentsci.0c00489
10.1021/acscentsci.0c00489 · External reference
Progress and prospect on imaging diagnosis of COVID-19
10.1007/s42058-020-00031-5 · 2020 · External reference
Remdesivir for the Treatment of Covid-19 — preliminary report
10.1056/nejmoa2007764 · 2020 · External reference
COVIDiagnosis-Net: deep Bayes-SqueezeNet based diagnosis of the coronavirus disease 2019 (COVID-19) from X-ray images
10.1016/j.mehy.2020.109761 · 2020 · External reference
Coronavirus Disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis
10.1016/j.jacr.2020.03.006 · 2020 · External reference
Incidence of ventilator-associated pneumonia in critically Ill children undergoing mechanical ventilation in pediatric intensive care unit
10.3390/children4070056 · 2017 · External reference
Unresolved reference
External reference
Utility of feline coronavirus antibody tests
10.1177/1098612x14538873 · 2014 · External reference
Chest imaging in patients hospitalized With COVID-19 infection - a case series
10.1067/j.cpradiol.2020.04.001 · 2020 · External reference
Ventilator-associated pneumonia in critically Ill patients with intensive antibiotic usage
1969 · External reference
Point-of-care multi-organ ultrasound improves diagnostic accuracy in adults presenting to the emergency department with acute dyspnea
10.5811/westjem.2015.11.28525 · 2016 · External reference
Elevated troponin in patients with coronavirus disease 2019: possible mechanisms
10.1016/j.cardfail.2020.04.009 · 2020 · External reference
10.1016/j.jmii.2020.02.012
10.1016/j.jmii.2020.02.012 · External reference
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study
2020 · External reference
From SARS to COVID-19: a previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach
10.1016/j.onehlt.2020.100124 · 2020 · External reference
COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review
10.1016/j.ejro.2020.100231 · 2020 · External reference
First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA
10.1016/s0140-6736(20)30607-3 · 2020 · External reference
Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view
10.1016/j.nmni.2020.100672 · 2020 · External reference
Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis
2020 · External reference
10.1016/s0140-6736(20)30154-9
10.1016/s0140-6736(20)30154-9 · External reference
10.1016/s0140-6736(20)30317-2
10.1016/s0140-6736(20)30317-2 · External reference
Recent advances in pathophysiology, drug development and future perspectives of SARS-CoV-2
10.3389/fcell.2020.580202 · 2020 · External reference
Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19
10.3390/v12050486 · 2020 · External reference
Are children less susceptible to COVID-19?
10.1016/j.jmii.2020.02.011 · 2020 · External reference
10.1016/s0140-6736(20)31208-3
10.1016/s0140-6736(20)31208-3 · External reference
2019 Novel Coronavirus (COVID-19) pandemic: built environment considerations to reduce transmission
10.1128/msystems.00245-20 · 2020 · External reference
10.1186/s12967-020-02344-6
10.1186/s12967-020-02344-6 · External reference
10.1016/j.tips.2020.03.006
10.1016/j.tips.2020.03.006 · External reference
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
2020 · External reference
Epidemiological and Clinical Aspects of COVID-19; a Narrative Review
2020 · External reference
10.1007/s00134-020-06033-2
10.1007/s00134-020-06033-2 · External reference
Genotype and phenotype of COVID-19: their roles in pathogenesis
2020 · External reference
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers
10.1183/13993003.01028-2020 · 2020 · External reference
The rationale for potential pharmacotherapy of COVID-19
10.3390/ph13050096 · 2020 · External reference
Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020
10.15585/mmwr.mm6913e2 · 2020 · External reference
Therapeutic management of patients with COVID-19: a systematic review
10.1016/j.infpip.2020.100061 · 2020 · External reference
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
10.1128/jvi.00023-19 · 2019 · External reference
10.1016/j.jiph.2020.06.016
10.1016/j.jiph.2020.06.016 · External reference
Can an effective SARS-CoV-2 vaccine be developed for the older population?
10.1186/s12979-020-00180-2 · 2020 · External reference
Unresolved reference
External reference
Effective treatment of severe COVID-19 patients with tocilizumab
10.1073/pnas.2005615117 · 2020 · External reference
New Insights of Emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention
10.3389/fcell.2020.00410 · 2020 · External reference
Clinical trials on drug repositioning for COVID-19 treatment
2020 · External reference
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
10.1016/j.ijantimicag.2020.105949 · 2020 · External reference
Unresolved reference
External reference
Recommendations for Investigational COVID-19 Convalescent Plasma
2020 · External reference
Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis
10.1007/s11239-019-01940-8 · 2019 · External reference
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
2014 · External reference
10.1128/jvi.00433-14
10.1128/jvi.00433-14 · External reference
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models
10.1128/aac.01407-13 · 2014 · External reference
Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae
10.1128/jvi.02322-09 · 2010 · External reference
10.2217/fvl.11.33
10.2217/fvl.11.33 · External reference
Structure and inhibition of the SARS coronavirus envelope protein ion channel
10.1371/journal.ppat.1000511 · 2009 · External reference
Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication
2009 · External reference
10.1074/jbc.m901547200
10.1074/jbc.m901547200 · External reference
10.1016/j.antiviral.2014.12.015
10.1016/j.antiviral.2014.12.015 · External reference
Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators
10.1038/srep39454 · 2016 · External reference
BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
10.1016/j.jiph.2016.04.002 · 2016 · External reference
10.1016/j.coviro.2019.04.002
10.1016/j.coviro.2019.04.002 · External reference
10.1128/aac.00957-12
10.1128/aac.00957-12 · External reference
10.1128/aac.02994-14
10.1128/aac.02994-14 · External reference
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension
2018 · External reference
10.1038/s41577-020-0323-4
10.1038/s41577-020-0323-4 · External reference
10.1016/j.ejps.2020.105375
10.1016/j.ejps.2020.105375 · External reference
Unresolved reference
External reference
Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
2020 · External reference
Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
2020 · External reference
Safety and Immunity of Covid-19 aAPC Vaccine
2020 · External reference
Immunity and Safety of Covid-19 Synthetic Minigene Vaccin
2020 · External reference
A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)
2020 · External reference
Unresolved reference
2020 · External reference
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection
2020 · External reference
Unresolved reference
External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/s41467-020-16505-0
10.1038/s41467-020-16505-0 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/s41598-018-36910-2
10.1038/s41598-018-36910-2 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.Front Bioeng
2020 · External reference
Recent Progress on the Versatility of Virus-Like Particles
10.3390/vaccines8010139 · 2020 · External reference
Virus-Like Particles as an Instrument of Vaccine Production
10.1134/s0026893319030154 · 2019 · External reference
Immunological considerations for COVID-19 vaccine strategies
10.1038/s41577-020-00434-6 · 2020 · External reference
Unresolved reference
External reference
10.1038/s41577-020-00434-6
10.1038/s41577-020-00434-6 · External reference
Unresolved reference
External reference
10.1016/j.ebiom.2020.102743
10.1016/j.ebiom.2020.102743 · External reference
Francesca Micoli. OMV Vaccines and the Role of TLR Agonists in Immune Response
10.3390/ijms21124416 · 2020 · External reference
10.1038/nrmicro2090
10.1038/nrmicro2090 · External reference
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
10.3389/fphar.2020.01258 · 2020 · External reference
Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
10.1016/j.micpath.2020.104236 · 2020 · External reference
Unresolved reference
External reference
10.1080/21645515.2020.1825896
10.1080/21645515.2020.1825896 · External reference
10.12688/f1000research.25998.1
10.12688/f1000research.25998.1 · External reference
Unresolved reference
External reference
Single Intranasal (IN) Dose of M2SR (M2-Deficient Single Replication) Live Influenza Vaccine Protects Adults Against Subsequent Challenge with a Substantially Drifted H3N2 Strain
10.1093/ofid/ofz360.2425 · 2019 · External reference
Unresolved reference
External reference
10.1071/ma20028
10.1071/ma20028 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Developing Covid-19 Vaccines at Pandemic Speed
2020 · External reference
10.1126/science.abc1932
10.1126/science.abc1932 · External reference
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
2020 · External reference
10.1016/j.cell.2020.05.025
10.1016/j.cell.2020.05.025 · External reference
Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody
2020 · External reference
10.1038/s41586-020-2381-y
10.1038/s41586-020-2381-y · External reference
10.1038/s41586-020-2380-z
10.1038/s41586-020-2380-z · External reference
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
10.1093/abt/tbaa008 · 2020 · External reference
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
10.1126/science.abc7520 · 2020 · External reference
10.1126/science.abc5902
10.1126/science.abc5902 · External reference
10.1038/s41423-020-0426-7
10.1038/s41423-020-0426-7 · External reference
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
2020 · External reference
10.1016/j.chom.2020.06.010
10.1016/j.chom.2020.06.010 · External reference
10.1016/s2666-5247(20)30004-5
10.1016/s2666-5247(20)30004-5 · External reference
10.1016/j.cell.2020.04.031
10.1016/j.cell.2020.04.031 · External reference
10.1126/science.abc5881
10.1126/science.abc5881 · External reference
10.1038/s41586-020-2548-6
10.1038/s41586-020-2548-6 · External reference
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
10.1126/science.abd0827 · 2020 · External reference
10.1080/21645515.2020.1735227
10.1080/21645515.2020.1735227 · External reference
Strengths, weaknesses, opportunities and threats (SWOT) analysis of china’s prevention and control strategy for the COVID-19 epidemic
2020 · External reference
Application of refined management in prevention and control of the coronavirus disease 2019 epidemic in non-isolated areas of a general hospital
2020 · External reference
